164 related articles for article (PubMed ID: 7914053)
1. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.
Lewander T
Acta Psychiatr Scand Suppl; 1994; 380():64-7. PubMed ID: 7914053
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.
Lindström LH
Acta Psychiatr Scand Suppl; 1994; 380():74-6. PubMed ID: 7914054
[TBL] [Abstract][Full Text] [Related]
3. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Lapierre YD; Ancill R; Awad G; Bakish D; Beaudry P; Bloom D; Chandrasena R; Das M; Durand C; Elliott D
J Psychiatry Neurosci; 1992 Oct; 17(4):134-45. PubMed ID: 1450186
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptics and the neuroleptic-induced deficit syndrome.
Lewander T
Acta Psychiatr Scand Suppl; 1994; 380():8-13. PubMed ID: 7914056
[TBL] [Abstract][Full Text] [Related]
5. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
Kerwin RW
Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
[No Abstract] [Full Text] [Related]
6. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
[TBL] [Abstract][Full Text] [Related]
7. New antipsychotics in schizophrenia: the French experience.
Vanelle JM; Olié JP; Lévy-Soussan P
Acta Psychiatr Scand Suppl; 1994; 380():59-63. PubMed ID: 7914051
[TBL] [Abstract][Full Text] [Related]
8. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia.
Klieser E; Strauss WH; Lemmer W
Acta Psychiatr Scand Suppl; 1994; 380():68-73. PubMed ID: 8048341
[TBL] [Abstract][Full Text] [Related]
9. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
Lapierre YD; Nair NP; Chouinard G; Awad AG; Saxena B; Jones B; McClure DJ; Bakish D; Max P; Manchanda R
Acta Psychiatr Scand Suppl; 1990; 358():72-7. PubMed ID: 1978496
[TBL] [Abstract][Full Text] [Related]
10. The effect of neuroleptics on cognitive and psychomotor function.
King DJ
Br J Psychiatry; 1990 Dec; 157():799-811. PubMed ID: 1981157
[TBL] [Abstract][Full Text] [Related]
11. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
Deo R; Soni S; Rastogi SC; Levine S; Plant I; Edwards JG; Mitchell M; Chanas A
Acta Psychiatr Scand Suppl; 1990; 358():120-4. PubMed ID: 1978470
[TBL] [Abstract][Full Text] [Related]
12. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
13. Psychomotor impairment and cognitive disturbances induced by neuroleptics.
King DJ
Acta Psychiatr Scand Suppl; 1994; 380():53-8. PubMed ID: 7914050
[TBL] [Abstract][Full Text] [Related]
14. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
Ahlfors UG; Rimön R; Appelberg B; Hagert U; Harma P; Katila H; Mahlanen A; Mehtonen OP; Naukkarinen H; Outakoski J
Acta Psychiatr Scand Suppl; 1990; 358():99-103. PubMed ID: 1978501
[TBL] [Abstract][Full Text] [Related]
15. [New psychopharmacologic alternatives in treatment of schizophrenia].
Bryois C
Schweiz Arch Neurol Psychiatr (1985); 1994; 145(6):19-24. PubMed ID: 7533941
[TBL] [Abstract][Full Text] [Related]
16. Remoxipride in schizophrenia: effects on plasma prolactin.
Chouinard G; Turnier L; Kallai-Sanfacon MA
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
[TBL] [Abstract][Full Text] [Related]
19. Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Wålinder J; Holm AC
Acta Psychiatr Scand Suppl; 1990; 358():158-63. PubMed ID: 1978477
[TBL] [Abstract][Full Text] [Related]
20. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
Wadworth AN; Heel RC
Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
